Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide rights to technology and intellectual property for novel synthetic therapies against cancer, infectious diseases and new immune activators. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock opened today at $9.01 and is currently trading at $8.92. The stock showed a negative weekly performance of -17.72%.
StemCells Inc (Nasdaq:STEM) announced one promotion and three new appointments to the Company’s executive team. Stephen Huhn, M.D., F.A.C.S., F.A.A.P. has been promoted to the newly created position of vice president, CNS clinical research and chief medical officer. Joel Naor, M.D., M.B.A., M.Sc., has joined StemCells, Inc. as vice president, clinical development, ophthalmology, and will report to Dr. Stephen Huhn; Naymisha Patel has joined StemCells, Inc. as vice president, quality systems; and Mohammad A. El-Kalay, Ph.D. has joined StemCells, Inc. as vice president, process development. StemCells Inc (NASDAQ:STEM) stock opened at $1.53, in current trading session and currently is at $1.61, by gaining 4.48%. The 52 week range is $1.15 – $1.84. Company’s market capitalization is $89.32 million.
On June 12, 2014, Actavis plc (NYSE:ACT) announced that Forest Laboratories, Inc. (FRX) has received valid consents (the “Requisite Consents”) from holders of a majority in aggregate principal amount of each series of Forest’s securities listed in the table below (the “FRX Notes”) to the elimination of Forest’s contractual registration rights obligations with respect to each series of FRX Notes (the “Proposed Amendments”) (collectively, the “Consent Solicitations”). Actavis plc (NYSE:ACT) stock is currently trading at $213.10. The EPS of the stock is -3.93. Company’s market capitalization is $36.70 billion.
Kindred Healthcare Inc. (NYSE:KND) is having another go at acquiring its reluctant target, Gentiva Health Services (GTIV_), by launching an all-cash tender offer to acquire all outstanding shares of the company’s common stock for $14.50 per share. Kindred Healthcare, Inc. (NYSE:KND) stock opened the session at $24.75, and now is at $24.75. The 52 week range of the stock remained $12.50 – $26.81 and the day range was $24.12 – $25.30.
One such stock that you may want to consider dropping is Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in RNN, according to Zack. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock opened today at $0.89 and is currently trading at $0.915. The stock showed a positive weekly performance of 1.11%.